Screener
TG Therapeutics TGTX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Net cash used in investing activities | (8,834) | (16,926) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Payment of loan payable | (255,000) | — |
| Proceeds from exercise of options | 848 | 453 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (12,998) |
| Net cash provided by (used in) financing activities | 390,914 | (12,545) |
Document
FAQ
- What is TG Therapeutics's stock issuance proceeds?
- TG Therapeutics (TGTX) reported stock issuance proceeds of $85K in Q2 2026.
- How has TG Therapeutics's stock issuance proceeds changed year-over-year?
- TG Therapeutics's stock issuance proceeds decreased by 80.3% year-over-year, from $432K to $85K.
- What is the long-term trend for TG Therapeutics's stock issuance proceeds?
- Over 3 years (2021 to 2025), TG Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $2.22M to $0.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about TG Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude